Roth Capital Has Negative Forecast for MGRM Q3 Earnings

Key Points

• Roth Capital has revised its Q3 2025 earnings per share (EPS) estimate for Monogram Orthopaedics to ($0.18), down from a prior estimate of ($0.13).
• Monogram Orthopaedics' stock opened at $5.46, with a 52-week low of $1.92 and a high of $6.02.
• A range of institutional investors have increased their stakes in Monogram Orthopaedics, indicating a growing interest despite the recent earnings miss.

Monogram Orthopaedics Inc. (NASDAQ:MGRM - Free Report) - Stock analysts at Roth Capital lowered their Q3 2025 earnings estimates for shares of Monogram Orthopaedics in a report issued on Tuesday, August 19th. Roth Capital analyst J. Wittes now anticipates that the company will post earnings of ($0.18) per share for the quarter, down from their previous forecast of ($0.13). The consensus estimate for Monogram Orthopaedics' current full-year earnings is ($0.49) per share. Roth Capital also issued estimates for Monogram Orthopaedics' Q4 2025 earnings at ($0.16) EPS, FY2025 earnings at ($0.59) EPS, Q1 2026 earnings at ($0.17) EPS, Q2 2026 earnings at ($0.18) EPS, Q3 2026 earnings at ($0.16) EPS, Q4 2026 earnings at ($0.15) EPS, FY2026 earnings at ($0.66) EPS, FY2027 earnings at ($0.52) EPS, FY2028 earnings at ($0.11) EPS and FY2029 earnings at $0.21 EPS.

Monogram Orthopaedics Price Performance

Shares of MGRM stock traded up $0.14 during mid-day trading on Friday, hitting $5.64. The stock had a trading volume of 67,533 shares, compared to its average volume of 404,759. The firm's 50-day moving average is $4.62 and its two-hundred day moving average is $3.33. Monogram Orthopaedics has a 12-month low of $1.92 and a 12-month high of $6.02. The firm has a market capitalization of $229.16 million, a P/E ratio of -11.26 and a beta of 0.69.

Monogram Orthopaedics (NASDAQ:MGRM - Get Free Report) last issued its earnings results on Friday, August 15th. The company reported ($0.16) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.11) by ($0.05).

Hedge Funds Weigh In On Monogram Orthopaedics

Institutional investors have recently made changes to their positions in the stock. Geode Capital Management LLC boosted its stake in Monogram Orthopaedics by 7.7% during the 4th quarter. Geode Capital Management LLC now owns 226,378 shares of the company's stock valued at $537,000 after acquiring an additional 16,234 shares during the last quarter. Wells Fargo & Company MN lifted its holdings in Monogram Orthopaedics by 286.6% during the 4th quarter. Wells Fargo & Company MN now owns 11,597 shares of the company's stock worth $27,000 after buying an additional 8,597 shares in the last quarter. Northern Trust Corp increased its holdings in Monogram Orthopaedics by 110.6% during the 4th quarter. Northern Trust Corp now owns 45,873 shares of the company's stock worth $109,000 after purchasing an additional 24,088 shares in the last quarter. Jane Street Group LLC acquired a new stake in Monogram Orthopaedics during the fourth quarter worth approximately $25,000. Finally, Focus Partners Advisor Solutions LLC grew its stake in shares of Monogram Orthopaedics by 6.1% during the first quarter. Focus Partners Advisor Solutions LLC now owns 213,678 shares of the company's stock worth $628,000 after buying an additional 12,328 shares during the last quarter. 0.45% of the stock is owned by institutional investors and hedge funds.

About Monogram Orthopaedics

Monogram Orthopaedics, Inc focuses on developing a product solution architecture to enable patient-optimized orthopaedic implants. The company intends to produce and market robotic surgical equipment and related software, orthopedic implants, tissue ablation tools, navigation consumables, and other miscellaneous instrumentation for use in reconstructive joint replacement procedures.